Skip to main content
    1

    10X Genomics Inc (TXG)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $54.99
    -3.20 (-5.50%)

    Market Cap: $7.65B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    10X Genomics Inc (TXG) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    10X Genomics reported revenue of $642.82M for the fiscal year ended Dec 31, 2025, up 5.2% from the year before. That year, net income was -$43.54M with a net margin of -6.8%, operating cash flow was $136.05M and free cash flow was $130.12M. The quarter ended Sep 30, 2026 had revenue of $150.67M and net income of -$19.43M.

    Revenue and Margins

    The operating margin was -9.5% in the fiscal year ended Dec 2025, the highest of the 8 years shown with an operating margin. Over the 8 years to Dec 2025, revenue grew from $71.08M, a compound annual rate of 31.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$642.82M+5.2%69.1%-9.5%-6.8%
    Dec 2024$610.78M-1.3%67.9%-31.9%-29.9%
    Dec 2023$618.73M+19.8%66.2%-42.9%-41.2%
    Dec 2022$516.41M+5.3%76.7%-32.5%-32.1%
    Dec 2021$490.49M+64.1%84.9%-10.7%-11.9%
    Dec 2020$298.85M+21.5%80.4%-178.7%-181.6%
    Dec 2019$245.89M+68.1%75.2%-12.4%-12.7%
    Dec 2018$146.31M+105.8%80.4%-75.7%-76.9%
    Dec 2017$71.08MN/A85.1%-25.8%-26.4%
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$642.82M$610.78M$618.73M$516.41M$490.49M$298.85M$245.89M$146.31M$71.08M
    Cost of revenue$198.94M$196.30M$209.41M$120.39M$74.09M$58.47M$61.03M$28.66M$10.56M
    Gross profit$443.88M$414.48M$409.31M$396.02M$416.40M$240.38M$184.86M$117.65M$60.52M
    Research and development$238.63M$264.70M$331.31M$265.67M$211.75M$570.92M$83.10M$109.90M$32.16M
    Operating income-$60.98M-$194.56M-$265.33M-$167.94M-$52.25M-$534.14M-$30.57M-$110.76M-$18.38M
    Net income-$43.54M-$182.63M-$255.10M-$166.00M-$58.22M-$542.73M-$31.25M-$112.48M-$18.76M
    EBITDA-$16.14M-$152.92M-$222.00M-$135.14M-$24.80M-$513.77M-$23.59M-$106.65M-$13.78M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$150.67M$151.04M$150.84M$166.03M$149.00M$172.91M$154.88M$165.02M$151.65M$153.10M$141.01M$183.98M
    Gross profit$112.93M$112.50M$106.18M$113.05M$100.31M$125.08M$105.44M$110.95M$106.39M$104.22M$92.91M$115.78M
    Operating income-$16.06M-$19.55M-$17.05M-$19.54M-$32.24M$30.13M-$39.33M-$49.84M-$41.48M-$41.74M-$61.50M-$55.19M
    Net income-$19.43M-$17.93M-$13.47M-$16.25M-$27.47M$34.54M-$34.36M-$49.03M-$35.75M-$37.90M-$59.95M-$48.95M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $10.98M by $462.98M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$1.04B$918.64M$965.14M$1.03B$1.02B$929.34M$605.92M$124.31M$75.61M
    Current assets$684.45M$584.39M$596.02M$635.03M$747.59M$774.37M$480.84M$106.24M$68.11M
    Cash and equivalents$473.97M$344.07M$359.28M$219.75M$587.45M$663.60M$424.17M$65.08M$47.86M
    Total liabilities$245.04M$208.50M$224.10M$223.24M$201.26M$190.27M$185.84M$101.05M$188.12M
    Short-term debt$10.98M$9.29M$11.52M$9.04M$5.13M$5.94M$9.88M$4.19M$4.22M
    Long-term debtN/AN/AN/AN/AN/AN/A$19.84M$25.49M$6.33M
    Shareholder equity$796.33M$710.13M$741.04M$805.74M$817.57M$739.07M$420.08M-$219.99M-$112.51M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.06B$1.03B$1.02B$1.04B$1.03B$979.97M$903.39M$918.64M$937.79M$929.67M$922.91M$965.14M
    Total liabilities$225.09M$204.52M$201.44M$245.04M$242.24M$206.69M$196.50M$208.50M$214.99M$205.61M$204.08M$224.10M
    Cash and equivalents$526.19M$502.51M$490.29M$473.97M$432.51M$397.71M$377.06M$344.07M$398.16M$379.82M$355.78M$359.28M
    Shareholder equity$838.04M$825.55M$814.32M$796.33M$785.12M$773.28M$706.89M$710.13M$722.80M$724.06M$718.83M$741.04M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 95.6% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow$136.05M$6.66M-$15.20M-$33.61M-$21.37M-$217.90M$34.63M-$76.41M-$10.70M
    Capital expenditures$5.93M$12.39M$48.60M$131.66M$101.28M$36.67M$42.74M$6.28M$3.76M
    Free cash flow$130.12M-$5.73M-$63.80M-$165.27M-$122.65M-$254.56M-$8.12M-$82.69M-$14.46M
    Share repurchasesN/AN/AN/AN/AN/AN/AN/AN/A$80.00K
    Investing cash flow-$13.44M-$32.63M$133.49M-$350.89M-$106.73M-$38.39M-$42.77M-$6.71M-$3.76M
    Financing cash flow$6.80M$10.91M$13.67M$15.82M$35.30M$468.91M$414.59M$105.37M$20.58M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$15.83M$16.97M$26.12M$40.78M$43.21M$17.71M$34.35M-$6.75M$21.64M$7.50M-$15.72M$25.76M
    Capital expenditures$971.00K$1.59M$1.60M$1.78M$687.00K$1.58M$1.89M$2.72M$3.89M$2.88M$2.91M$3.45M
    Free cash flow$14.86M$15.39M$24.52M$39.00M$42.53M$16.13M$32.46M-$9.46M$17.75M$4.62M-$18.64M$22.31M
    Last 12 quarters

    Frequently Asked Questions About TXG

    What is 10X Genomics' annual revenue?

    10X Genomics reported revenue of $642.82M for the fiscal year ended Dec 31, 2025.

    How fast is 10X Genomics' revenue growing?

    Revenue was up 5.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 7.6%.

    Is 10X Genomics profitable?

    No. 10X Genomics reported net income of -$43.54M for the fiscal year ended Dec 31, 2025, with a net margin of -6.8%.

    How much free cash flow does TXG generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $136.05M minus capital expenditures of $5.93M produced free cash flow of $130.12M.

    How much debt does 10X Genomics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $10.98M and cash and equivalents of $473.97M.